176 related articles for article (PubMed ID: 19739275)
21. Lysophosphatidic acid receptors in cancer pathobiology.
Tsujiuchi T; Araki M; Hirane M; Dong Y; Fukushima N
Histol Histopathol; 2014 Mar; 29(3):313-21. PubMed ID: 24194373
[TBL] [Abstract][Full Text] [Related]
22. Lysophosphatidic acid is a major regulator of growth-regulated oncogene alpha in ovarian cancer.
Lee Z; Swaby RF; Liang Y; Yu S; Liu S; Lu KH; Bast RC; Mills GB; Fang X
Cancer Res; 2006 Mar; 66(5):2740-8. PubMed ID: 16510595
[TBL] [Abstract][Full Text] [Related]
23. Roles of LPA in ovarian cancer development and progression.
Pua TL; Wang FQ; Fishman DA
Future Oncol; 2009 Dec; 5(10):1659-73. PubMed ID: 20001802
[TBL] [Abstract][Full Text] [Related]
24. The Rho/ROCK pathway for lysophosphatidic acid-induced proteolytic enzyme expression and ovarian cancer cell invasion.
Jeong KJ; Park SY; Cho KH; Sohn JS; Lee J; Kim YK; Kang J; Park CG; Han JW; Lee HY
Oncogene; 2012 Sep; 31(39):4279-89. PubMed ID: 22249252
[TBL] [Abstract][Full Text] [Related]
25. Bovine ovarian follicular growth and development correlate with lysophosphatidic acid expression.
Sinderewicz E; Grycmacher K; Boruszewska D; Kowalczyk-Zięba I; Staszkiewicz J; Ślężak T; Woclawek-Potocka I
Theriogenology; 2018 Jan; 106():1-14. PubMed ID: 29028570
[TBL] [Abstract][Full Text] [Related]
26. SPARC inhibits LPA-mediated mesothelial-ovarian cancer cell crosstalk.
Said NA; Najwer I; Socha MJ; Fulton DJ; Mok SC; Motamed K
Neoplasia; 2007 Jan; 9(1):23-35. PubMed ID: 17325741
[TBL] [Abstract][Full Text] [Related]
27. The lysophosphatidic acid (LPA) receptors their expression and significance in epithelial ovarian neoplasms.
Wang P; Wu X; Chen W; Liu J; Wang X
Gynecol Oncol; 2007 Mar; 104(3):714-20. PubMed ID: 17204312
[TBL] [Abstract][Full Text] [Related]
28. Alkoxymethylenephosphonate analogues of (Lyso) phosphatidic acid stimulate signaling networks coupled to the LPA2 receptor.
Gajewiak J; Tsukahara R; Tsukahara T; Fujiwara Y; Yu S; Lu Y; Murph M; Mills GB; Tigyi G; Prestwich GD
ChemMedChem; 2007 Dec; 2(12):1789-98. PubMed ID: 17952880
[TBL] [Abstract][Full Text] [Related]
29. Lysophosphatidic acid induction of urokinase plasminogen activator secretion requires activation of the p38MAPK pathway.
Estrella VC; Eder AM; Liu S; Pustilnik TB; Tabassam FH; Claret FX; Gallick GE; Mills GB; Wiener JR
Int J Oncol; 2007 Aug; 31(2):441-9. PubMed ID: 17611702
[TBL] [Abstract][Full Text] [Related]
30. Lysophosphatidic acid and its role in reproduction.
Budnik LT; Mukhopadhyay AK
Biol Reprod; 2002 Apr; 66(4):859-65. PubMed ID: 11906902
[TBL] [Abstract][Full Text] [Related]
31. Lysophosphatidylethanolamine utilizes LPA(1) and CD97 in MDA-MB-231 breast cancer cells.
Park SJ; Lee KP; Kang S; Chung HY; Bae YS; Okajima F; Im DS
Cell Signal; 2013 Nov; 25(11):2147-54. PubMed ID: 23838008
[TBL] [Abstract][Full Text] [Related]
32. Gene regulatory networking reveals the molecular cue to lysophosphatidic acid-induced metabolic adaptations in ovarian cancer cells.
Ray U; Roy Chowdhury S; Vasudevan M; Bankar K; Roychoudhury S; Roy SS
Mol Oncol; 2017 May; 11(5):491-516. PubMed ID: 28236660
[TBL] [Abstract][Full Text] [Related]
33. Lysophospholipid growth factors in the initiation, progression, metastases, and management of ovarian cancer.
Fang X; Gaudette D; Furui T; Mao M; Estrella V; Eder A; Pustilnik T; Sasagawa T; Lapushin R; Yu S; Jaffe RB; Wiener JR; Erickson JR; Mills GB
Ann N Y Acad Sci; 2000 Apr; 905():188-208. PubMed ID: 10818454
[TBL] [Abstract][Full Text] [Related]
34. The NF-κB pathway mediates lysophosphatidic acid (LPA)-induced VEGF signaling and cell invasion in epithelial ovarian cancer (EOC).
Dutta S; Wang FQ; Wu HS; Mukherjee TJ; Fishman DA
Gynecol Oncol; 2011 Oct; 123(1):129-37. PubMed ID: 21782227
[TBL] [Abstract][Full Text] [Related]
35. TAZ mediates lysophosphatidic acid-induced migration and proliferation of epithelial ovarian cancer cells.
Jeong GO; Shin SH; Seo EJ; Kwon YW; Heo SC; Kim KH; Yoon MS; Suh DS; Kim JH
Cell Physiol Biochem; 2013; 32(2):253-63. PubMed ID: 23942151
[TBL] [Abstract][Full Text] [Related]
36. Hypoxia enhances lysophosphatidic acid responsiveness in ovarian cancer cells and lysophosphatidic acid induces ovarian tumor metastasis in vivo.
Kim KS; Sengupta S; Berk M; Kwak YG; Escobar PF; Belinson J; Mok SC; Xu Y
Cancer Res; 2006 Aug; 66(16):7983-90. PubMed ID: 16912173
[TBL] [Abstract][Full Text] [Related]
37. The autotaxin-lysophosphatidic acid-lysophosphatidic acid receptor cascade: proposal of a novel potential therapeutic target for treating glioblastoma multiforme.
Tabuchi S
Lipids Health Dis; 2015 Jun; 14():56. PubMed ID: 26084470
[TBL] [Abstract][Full Text] [Related]
38. Lysophosphatidic acid signaling in ovarian cancer.
Jesionowska A; Cecerska-Heryc E; Matoszka N; Dolegowska B
J Recept Signal Transduct Res; 2015; 35(6):578-84. PubMed ID: 26393967
[TBL] [Abstract][Full Text] [Related]
39. Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells.
Fang X; Yu S; Bast RC; Liu S; Xu HJ; Hu SX; LaPushin R; Claret FX; Aggarwal BB; Lu Y; Mills GB
J Biol Chem; 2004 Mar; 279(10):9653-61. PubMed ID: 14670967
[TBL] [Abstract][Full Text] [Related]
40. Lysophosphatidic acid (LPA) signalling in cell migration and cancer invasion: a focussed review and analysis of LPA receptor gene expression on the basis of more than 1700 cancer microarrays.
Willier S; Butt E; Grunewald TG
Biol Cell; 2013 Aug; 105(8):317-33. PubMed ID: 23611148
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
